معرفی
Giulio Stefanini serves as Associate Professor of Cardiology at Humanitas University and Clinical and Interventional Cardiologist at IRCCS Humanitas Research Hospital and Humanitas S.Pio X Hospital in Milan. He leads clinical research for the Cardio Center at Humanitas Research Hospital, directing studies on complex cardiovascular interventions and outcomes.
His educational background includes:
- Medical degree from Sapienza University of Rome
- PhD in Experimental Medicine
- MSc in Health Economics, Outcomes and Management in Cardiovascular Sciences from London School of Economics
Professor Stefanini's research spans interventional cardiology with emphasis on coronary artery disease, transcatheter valve procedures, and antiplatelet therapy optimization. He integrates advanced imaging techniques like cardiac MRI and intravascular ultrasound with health economics analysis to improve procedural outcomes and patient management. His work frequently addresses high-bleeding-risk scenarios and complex vascular access challenges.
Recent publications demonstrate concentrated focus on TAVR innovations, drug-coated balloon applications, AI-driven risk prediction, and in-silico procedural simulation. Key trends include personalized antiplatelet duration, mitral valve interventions, and registry-based evidence for complex coronary lesions.
His scientific recognition includes:
- Fellow of the European Society of Cardiology (FESC)
- William Harvey Award from Italian Society of Cardiology
- Health Young Physician Leaders (YPL) programme nomination
- Multiple research grants from ESC and EAPCI
Professor Stefanini has secured competitive funding including the Swiss National Science Foundation's SPUM grant and EAPCI research support. His leadership in the Cardio Center coordinates multicenter registries like HOSTILE and ULTRA-BIFURCAT. Current projects emphasize procedural standardization, minimalistic interventional approaches, and cardiovascular safety of emerging therapies.
He directs the Cardio Center's clinical research activities, overseeing trials in complex PCI, structural heart disease, and cardiovascular outcomes research.
